Fig. 7: SNHG26 promoted TSCC growth by inhibiting NK cells in vivo.
From: Exosomal SNHG26 mediates immunosuppression by impairing NK cells in tongue cancer
A The construction process of PBMC humanized mouse model for TSCC (huPBMC-NSG). B Appearance of the huPBMC-NSG and identification of TSCC by HE staining (Scale: 1 mm). C Flow cytometry was used to identify human immune cell components (hCD45 + mCD45-) and determine the proportion of Marker cells within the human cell population. D The quantification of tumor tissue volume and weight in the Vector and OE-SNHG26 cohorts of huPBMC-NSG. E The FISH&mIF assays were employed to compare the expression levels of SNHG26 and CD56 in the Vector and OE-SNHG26 groups (Scale: 100 μm). F The expression levels of SNHG26, HLA-DRA, and TGFB1 were compared between the NC and OE groups using qRT-PCR or IF experiments (Scale: 20 μm). OE overexpression. Compare each group with the NC group when there is no special identification on the statistical chart; *p < 0.05, **p < 0.01, ***p < 0.001. The figures were generated using GraphPad Prism (version 9.0) and Figdraw.
